- Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder
- The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment
- Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of neurological conditions
- The patent application bolsters Odyssey’s growing list of medical devices, which currently comprise a CardioMap, a heart monitoring and screening device, as well as Save-A-Life, a handheld choking rescue device
Odyssey Health (OTC: ODYY), a medical enterprise focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, just announced filing for the United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device. This comes on the heels of the successful completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial, which saw the successful use of the device, and a proven safety profile of the company’s concussion pharmaceutical treatment.
“Following the completion of this Phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment,” noted Michael Redmond, Odyssey’s CEO.
“I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting,” he added (https://ibn.fm/0Gf75).
The Nasal Device was designed to create an adequate airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for quick and direct diffusion into the brain to treat central nervous system (“CNS”) injury, disease, or disorder. The concussion drug candidate is designed to be administered within a few minutes of a concussive episode, thereby inducing intracellular steroid receptors in brain cells and activating multiple gene response elements that reduce swelling, oxidative stress, and inflammation in the brain. This, in turn, restores proper blood flow to the brain while also avoiding drug-induced fatigue or cognitive decline associated with the prolonged use of drugs associated with concussion treatment (https://ibn.fm/lO3jW).
The patent application bolsters Odyssey’s growing list of medical devices that currently comprise a CardioMap – a heart monitoring and screening device for early detection of coronary artery disease, as well as Save-A-Life- a handheld choking rescue device.
Mr. Redmond has expressed the company’s pleasure in the functionality and performance of the Nasal Device, citing how it provides a significant opportunity and advantage for treating neurological conditions.
“We were very pleased with the functionality and performance of the Nasal Device during the Phase I study and its administration of Odyssey’s concussion drug. The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects is a huge advantage in the development of safe and efficacious treatments,” he noted.
“Odyssey’s novel Nasal Device provides that opportunity and advantage,” he added (https://ibn.fm/RBlhR).
Odyssey is still identifying Phase II trial sites and structuring the study design with the site’s medical leadership and the Odyssey Medical Advisors. The company looks to make further use of the Nasal Device in this phase of the study, while also building on the success of the previous research as it works towards approval by the U.S. Food and Drug Administration (“FDA”).
For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.